drugset / Trial / NCT00537667

The SPECTRA Study

NCT00537667

Phase 2 Terminated 22 enrolled Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare IL-1ra and the combination of IL-1ra and PEGsTNF-RI with respect to their ability to reduce inflammation and bone and cartilage destruction in the synovium of subjects with rheumatoid arthritis.

Timeline

Start
2001-08
Primary completion
2003-03
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anakinra Protein / enzyme biologic
Subject PEG sTNF-R1 Unknown

Indications